The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
m EHA 2026, Dr. Loretta Nastoupil interviews Dr. Georg Lenz on the phase 3 FRONTMIND study, a randomised, double-blind, placebo-controlled study that evaluated tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma.
ASCO’s first guideline on ctDNA testing in solid tumors and lymphoma was published by Christina Lockwood, PhD, head of the Genetics and Solid Tumors Laboratory at the University of Washington Medical Center, in the Journal of Clinical Oncology in June.
The US Food and Drug Administration has accepted a new drug application for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma.
The assay supports treatment evaluation and risk stratification by detecting residual disease or early reemergence that standard testing might miss.
Dr. Campelo outlines safety and efficacy data for this novel TGF-beta pathway inhibitor, highlighting transfusion independence rates, overall response rates, and safety outcomes in lower-risk MDS, including difficult-to-treat patient subgroups.
The society is excited to announce the first episode of its educational podcast, SOHO Spotlight.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
![Insider_YT_Feature_Pannunzio_CLFR2_400x400[15]](https://sohoinsider.com/wp-content/uploads/2026/06/Insider_YT_Feature_Pannunzio_CLFR2_400x40015.png)
